Search Results - "Thåström, A."

Nucleosomal Locations of Dominant DNA Sequence Motifs for Histone–DNA Interactions and Nucleosome Positioning by Thåström, A., Bingham, L.M., Widom, J.

“…DNA sequence is an important determinant of the positioning, stability, and activity of nucleosomes, yet the molecular basis of these effects remains elusive…”
Get full text

Spontaneous Access of Proteins to Buried Nucleosomal DNA Target Sites Occurs via a Mechanism That Is Distinct from Nucleosome Translocation by Anderson, J. D., Thåström, A., Widom, J.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Measurement of histone-DNA interaction free energy in nucleosomes by Thåström, A, Lowary, P T, Widom, J

“…Nucleosome positioning DNA sequences are of increasing interest because of their proposed roles in gene regulation and other chromosome functions in vivo, and…”
Get full text

Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC) by Galsky, M.D., Banchereau, R., Kadel, E.E., Ramirez-Montagut, T., Mariathasan, S., Thåström, A., Rosenberg, J., Powles, T., van der Heijden, M.S., Necchi, A.

Get full text

Sequence motifs and free energies of selected natural and non-natural nucleosome positioning DNA sequences by Thåström, A, Lowary, P.T, Widlund, H.R, Cao, H, Kubista, M, Widom, J

“…Our laboratories recently completed SELEX experiments to isolate DNA sequences that most-strongly favor or disfavor nucleosome formation and positioning, from…”
Get full text

Histone−DNA Binding Free Energy Cannot Be Measured in Dilution-Driven Dissociation Experiments by Thåström, A, Gottesfeld, J. M, Luger, K, Widom, J

“…Despite decades of study on nucleosomes, there has been no experimental determination of the free energy of association between histones and DNA. Instead, only…”
Get full text

902PBiological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC) by Galsky, M D, Banchereau, R, Kadel, E E, Ramirez-Montagut, T, Mariathasan, S, Thåström, A, Rosenberg, J, Powles, T, van der Heijden, M S, Necchi, A

Get full text

1142 Efficacy of atezolizumab (MPDL3280A) in platinum-treated metastatic urothelial carcinoma (mUC): Update from the IMvigor 210 phase II clinical trial by Van Der Heijden, M, Retz, M, Perez-Gracia, J.L, Necchi, A, Powles, T, Sridhar, S.S, Neigisch, G, Theodore, C, Bracarda, S, Duran, I, Carles, J, Rosenberg, J, Dreicer, R, Grande, E, Cui, N, Mariathasan, S, Thåström, A, Loriot, Y

Get full text

Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study by Loriot, Y., Rosenberg, J.E., Powles, T.B., Necchi, A., Hussain, S., Morales, R., Retz, M., Niegisch, G., Duran, I., Theodore, C., Perez-Gracia, J.L., Grande Pulido, E., Thåström, A., Danner, B., Mariathasan, S., Abidoye, O., van der Heijden, M.

Get full text

LBA14_PR - IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC) by Grande, E., Galsky, M., Arranz Arija, J.A., De Santis, M., Davis, I.D., De Giorgi, U.F.F., Mencinger, M., Kikuchi, E., Garcia del Muro, X., Gumus, M., Özgüroğlu, M., Rezazadeh Kalebasty, A., Park, S.H., Alekseev, B.Y., Schutz, F.A.B., Li, J.-R., Mecke, A., Mariathasan, S., Thastrom, A., Bamias, A.

“…First-line (1L) mUC treatment (tx) includes cisplatin (cis)- or carboplatin (carbo)-based chemotherapy or checkpoint inhibitors, depending on patient (pt)…”
Get full text

IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC) by Grande, E., Galsky, M., Arranz Arija, J.A., De Santis, M., Davis, I.D., De Giorgi, U.F.F., Mencinger, M., Kikuchi, E., Garcia del Muro, X., Gumus, M., Özgüroğlu, M., Rezazadeh Kalebasty, A., Park, S.H., Alekseev, B.Y., Schutz, F.A.B., Li, J.-R., Mecke, A., Mariathasan, S., Thastrom, A., Bamias, A.

Get full text

LBA14_PRIMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC) by Grande, E, Galsky, M, Arranz Arija, J A, De Santis, M, Davis, I D, De Giorgi, U F F, Mencinger, M, Kikuchi, E, Garcia del Muro, X, Gumus, M, Özgüroğlu, M, Rezazadeh Kalebasty, A, Park, S H, Alekseev, B Y, Schutz, F A B, Li, J-R, Mecke, A, Mariathasan, S, Thastrom, A, Bamias, A

“…Abstract Background First-line (1L) mUC treatment (tx) includes cisplatin (cis)- or carboplatin (carbo)-based chemotherapy or checkpoint inhibitors, depending…”
Get full text

Inherited mosaicism for the supernumerary marker chromosome in cat eye syndrome: Inter- and intra-individual variation and correlation to the phenotype by Kvarnung, Malin, Lindstrand, Anna, Malmgren, Helena, Thåström, Anders, Jacobson, Lena, Dahl, Niklas, Lundin, Johanna, Blennow, Elisabeth

“…We have studied a family with repeated transmission of mosaicism for a supernumerary marker chromosome (SMC), giving rise to varying symptoms of the cat eye…”
Get full text